Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/16172
Title: | A recombinant fragment of Human Surfactant Protein D induces apoptosis in pancreatic cancer cell lines via Fas-mediated pathway |
Authors: | Kaur, A Riaz, MS Murugaiah, V Varghese, PM Singh, SK Kishore, U |
Keywords: | pancreatic cancer;innate immunity;surfactant protein;SP-D;apoptosis;Immune surveillance |
Issue Date: | 4-Jun-2018 |
Citation: | Kaur, A., Riaz, M.S., Murugaiah, V., Varghese, P.M., Singh, S.K. and Kishore, U. (2018) 'A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway', Frontiers in Immunology, 9, 1126, pp. 1-10. doi: 10.3389/fimmu.2018.01126. |
Abstract: | Copyright: © 2018 Kaur, Riaz, Murugaiah, Varghese, Singh and Kishore. Human Surfactant Protein (SP-D) is a potent innate immune molecule, which is emerging as a key molecule in the recognition and clearance of altered and non-self targets. Previous studies have shown that a recombinant fragment of human SP-D (rfhSP-D) induced apoptosis via p53 mediated apoptosis pathway in an eosinophilic leukemic cell line, AML14.3D10. Here, we report the ability of rfhSP-D to induce apoptosis via TNF-α/Fas-mediated apoptosis pathway regardless of the p53 status in human pancreatic adenocarcinoma using Panc-1 (p53mt), MiaPaCa-2 (p53mt), and Capan-2 (p53wt) cell lines. Treatment of these cell lines with rfhSP-D for 24 h caused growth arrest in G1 cell cycle phase and triggered transcriptional upregulation of proapoptotic factors such as TNF-α and NF-κB. Translocation of NF-κB from the cytoplasm into the nucleus of pancreatic cancer cell lines was observed via immunofluorescence microscopy following treatment with rfhSP-D as compared to the untreated cells. The rfhSP-D treatment caused upregulation of pro-apoptotic marker Fas, as analyzed via qPCR and western blot, which then triggered caspase cascade, as evident from cleavage of caspase 8 and 3 analyzed via western blot at 48 h, and subsequent, apoptosis of the cells. The cell number following the rfhSP-D treatment was reduced in the order of Panc-1 (~67%) > MiaPaCa-2 (~60%) > Capan2 (~35%). Our studies appear to suggest that rfhSP-D can be used to therapeutically target pancreatic cancer cells irrespective of their p53 phenotype. |
URI: | https://bura.brunel.ac.uk/handle/2438/16172 |
DOI: | https://doi.org/10.3389/fimmu.2018.01126 |
Appears in Collections: | Brunel Library Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 10.24 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License